Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer

Clinical Cancer Research

Volumn 15, Issue 24, 2009, Pages 7693-7700

  Sparano, Joseph A ^a   Goldstein, Lori J ^a   Childs, Barrett H ^b   Shak, Steven ^c   Brassard, Diana ^b   Badve, Sunil ^a   Baehner, Frederick L ^c   Bugarini, Roberto ^c   Rowley, Steve ^b   Perez, Edith ^d   Shulman, Lawrence N ^e   Martino, Silvana ^f   Davidson, Nancy E ^a   Sledge Jr , George W ^a   Gray, Robert ^a  

^a Eastern Cooperative Oncology Group   (United States)

^b SANOFI   (France)

^c Genomic Health Inc   (United States)

^d North Central Cancer Treatment Group Rochester   (United States)

^e Cancer and Leukemia Group B   (United States)

^f Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RNA; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM;

EID: 73349122284     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1450     Document Type: Article

References (31)

1. The Early Breast Cancer Trialists. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006;106:2337-44.
3. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344:1997-2008.
4. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84.
6. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008;100:14-20.
7. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des 1990;5:307-17.
8. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24:2428-36.
9. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26:736-44.
10. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7.
11. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptorpositive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26:4063-71.
12. Goldstein LJ, O'Neill A, Sparano JA, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092-9.
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
14. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164: 35-42.
15. Rody A, Karn T, Ruckhaberle E, et al. Gene expression of topoisomerase II α (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009;113:457-66.
16. Badve SS, Baehner FL, Gray RP, et al. Estrogenand progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008;26:2473-81.
17. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
18. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18.
19. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25:2127-32.
20. Lin DY. On fitting Cox's proportional hazards model to survey data. Biometrika 2000;87:37-47.
21. Borgan O, Langholz B, Samuelsen SO, Goldstein L, Pagoda J. Exposure stratified case-cohort designs. Lifetime Data Analysis 2000;6:39-59.
22. Gray RJ. Weighted analysis for cohort sampling designs. Lifetime Data Anal 2009;15:24-40.
23. Korn EL, Troendle JF, McShane LM, Simon R. Controlling the number of false discoveries: application to high-dimensional genomic data. J Statist Plan and Infer 2004;124:379-398.
24. Korn EL, Li MC, McShane LM, Simon R. An investigation of two multivariate permutation methods for controlling the false discovery proportion. Stat Med 2007;26:4428-40.
25. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7:347-50.
26. Hu YC, Komorowski RA, Graewin S, et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003;9:4165-71.
27. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-24.
28. Wang TL, Diaz LA, Jr., Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 2004;101: 3089-94.
29. Albain K, BarlowW,Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ERpositive breast cancer (S8814,INT0100) [abstract 10]. San Antonio Breast Cancer Symposium 2007, abstract 10. www.sabcs.org.
30. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
31. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26: 721-8.